Introduction: Type 2 diabetes mellitus (T2DM)
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a disorder of blood glucose control that arises from multiple metabolic abnormalities: impaired response of liver and peripheral (muscle, adipose) tissues to the effects of insulin (i.e., insulin resistance); progressive loss of pancreatic beta-cell function (insufficient insulin secretion, reduced beta-cell sensitivity to glucose, decreased beta-cell mass); dysregulation of glucagon secretion; and altered incretin hormone physiology (Fig. 1 ) [1] . These defects all lead to high levels of postprandial and fasting blood glucose.
Early and effective treatment of T2DM is essential to minimize the microvascular and macrovascular complications associated with chronic hyperglycemia, but success remains limited. Only about half of patients with T2DM
in the United States (US) achieve the American Diabetes Association glycosylated hemoglobin (HbA 1c ) goal of <7.0% [2] and the proportion decreases as the HbA 1c target becomes more aggressive. A cross-sectional survey involving >17,000 patients in Japan found that just over one-third (36.8%) achieved the HbA 1c target goal of <6.9% as recommended by the Japan Diabetes Society [3] .
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Fig. 1 Major pathophysiological features of type 2 diabetes mellitus
Treatment of T2DM typically begins with diet/exercise followed by incremental additions of single antidiabetic agents as required, most commonly metformin or a sulfonylurea to achieve and maintain glycemic control. This approach is reactive rather than proactive as progression to the next level is based on treatment failure. Treatment by single oral agents are unable to address all the metabolic abnormalities that underlie T2DM and the ability to treat aggressively is often limited by dosedependent side effects [4] . As T2DM progresses, most patients require the addition of one or more antidiabetic agents to regain glycemic control. Combining agents with complementary mechanisms of action is a rational approach to addressing multiple defects in glycemic control with the potential of achieving additive clinical benefits [5] . However, multi-drug therapy can have a negative impact on patient adherence to treatment, particularly in the case of chronic diseases, such as T2DM [6] [7] [8] [9] .
Accordingly, interest is growing in the use of fixed-dose combinations of antidiabetic agents which are not only more convenient for patients, but also have the potential to improve adherence [10] . Many such combinations are possible, but one of considerable interest involves the dipeptidyl peptidase-4 (DPP-4) inhibitor and thiazolidinedione (TZD) classes of oral antidiabetic agents. DPP-4 inhibitors (or 'gliptins') act primarily by increasing pancreatic insulin secretion in response to nutrient intake [11, 12] , whereas TZDs act predominantly by improving the sensitivity of muscle and adipose tissue to insulin [13] . By addressing two of the fundamental defects in T2DM -namely, beta-cell dysfunction and insulin resistance -this combination offers scope for additive
efficacy.
An alogliptin-pioglitazone fixed-dose combination tablet was recently approved in 
METHODS
A MEDLINE search was performed using the key words "alogliptin" and "pioglitazone" to identify relevant articles for inclusion. A total of five randomized, controlled clinical studies of alogliptin-pioglitazone combination therapy up to and including May 2012 were identified and form the basis of this review. These studies were supplemented by major reviews and other important articles known to the authors.
PHARMACOLOGICAL RATIONALE FOR ALOGLIPTIN-PIOGLITAZONE COMBINATION
Pioglitazone
Pioglitazone is a potent insulin sensitizer.
It binds specifically to the peroxisome proliferatoractivated receptor gamma (PPARG) and enhances the sensitivity of liver, muscle, and adipose tissue to insulin (promoting the uptake of glucose into tissues), with a resulting decline in fasting and postprandial plasma glucose levels [14, 15] .
Pioglitazone also increases serum high-density lipoprotein (HDL)-cholesterol and decreases neutral fat [13] , whilst increasing the expression and differentiation of adiponectin, a hormone that enhances insulin sensitivity [16, 17] .
Several long-term (>1.5 years), double-blind, active comparator studies have consistently demonstrated that pioglitazone produces a durable decrease in HbA 1c levels [18] [19] [20] [21] [22] , a result which can be explained only by its ability to improve and preserve beta-cell function in patients with T2DM [23] . In other studies involving patients with T2DM, pioglitazone was shown to reduce the inflammatory response to a glucose challenge more than acarbose [24] and it was shown to be better than glibenclamide in mitigating variations in lipid parameters and inflammatory markers [25] .
Pioglitazone is well absorbed after oral administration and reaches maximum concentrations in approximately 1.5 h [26] .
Although metabolized by the hepatic cytochrome P450 enzyme system, there is no evidence to suggest that pioglitazone inhibits or induces any of the P450 isoenzymes involved in drug metabolism [27, 28] . The half-life of pioglitazone is approximately 9 h, but its glucose-lowering activity is extended by two active metabolites. The pharmacokinetic characteristics of pioglitazone are not significantly altered in patients with T2DM, renal or hepatic insufficiency, or in the elderly. Pioglitazone can be administered once daily without regard to meals [26] .
Alogliptin
Alogliptin is a potent and highly selective inhibitor of DPP-4, the enzyme responsible for rapid inactivation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) [12] .
GLP-1 and GIP are secreted in the intestine in response to food intake and stimulate insulin secretion from pancreatic beta cells in a glucosedependent manner. GLP-1 also suppresses glucagon secretion and enhances pancreatic beta-cell mass through increases in proliferation and decreases in apoptosis [1] . GLP-1 has been shown to lower glucose levels even in patients with severe beta-cell impairment, presumably as a result of lowered glucagon levels and other non-insulin related effects [29] . By preventing the degradation of GLP-1 (and GIP), alogliptin restores these endogenous hormones to normal physiological levels and extends their half-lives; thereby assisting in the maintenance of normal plasma glucose levels. The effects of alogliptin are observed predominantly after meals [30, 31] .
Alogliptin is rapidly absorbed after oral administration and reaches maximum plasma concentration in approximately 1-2 h. It has a mean half-life of 12-24 h [1, 31] . Alogliptin is only minimally metabolized and is excreted primarily unchanged in the urine (75%), necessitating dosage adjustments in renal but not hepatic impairment [31] . As alogliptin is neither an inhibitor nor an inducer of cytochrome P450
isoforms, there is a low likelihood of drugdrug interactions [32] . In multiple dose studies (14 days) of alogliptin, plasma DPP-4 activity was inhibited by >80% after 24 h, supporting once-daily dosing [31] .
Alogliptin-Pioglitazone Combination
Pharmacokinetic studies in healthy volunteers or pioglitazone monotherapy [34, 35] . The alogliptin-pioglitazone combination also increased pancreatic insulin content [34] [35] [36] , maintained islet structure [34] , and preserved islet mass [36] to a greater extent than either agent alone. (n = 493) who had failed to achieve adequate [41] pc, pg metformin (≥1,500 mg) or 45) (n = 1,554) A12.5 + P -1.4 P < 0.001 vs. P (15, 30, or 45) A25 + P -1.4 P < 0.001 vs. P (15, 30, or 45) A alogliptin (mg), db double-blind, HbA 1c glycosylated hemoglobin (NGSP value), M metformin, mc multicentre, P pioglitazone (mg), pc placebo-controlled, pg parallel group, PLA placebo, r randomized, TZD thiazolidinedione ≥ AE resulting in study discontinuation Fig. 2 Incidence of treatment-related AEs and study discontinuations due to AEs in patients with T2DM treated with add-on PLA, A12.5, or A25 to PIO ± metformin or sulfonylurea [35] . A alogliptin (mg), AE adverse event, PIO pioglitazone, T2DM type 2 diabetes mellitus Add-on alogliptin was generally well tolerated with no dose-related differences in the incidence of adverse effects. During the extension phase, the only drug-related AE with an incidence of ≥3% was edema (3% in the A25 group vs. 1.2%
CLINICAL EVIDENCE FOR ALOGLIPTIN-PIOGLITAZONE COMBINATION
in the A12.5 group), but this was generally mild and is likely to have been related to pioglitazone.
Alogliptin has also been investigated as a third oral antidiabetic drug in patients failing to achieve adequate glycemic control whilst receiving combination treatment with metformin (≥1,500 mg or maximum tolerated dose) and P30 [40] . This study compared the (Table 1) , and efficacy was independent of gender, age, race, ethnicity, and baseline BMI. Alogliptin add-on therapy produced significantly (P < 0.01) greater decreases in FPG at all time points and significantly more patients receiving add-on alogliptin achieved an HbA 1c of ≤7.0% compared Table 2 Changes from baseline in several glycemic/metabolic parameters in Japanese patients treated for 12 weeks with addon PLA or alogliptin (A12.5 or A25) to pioglitazone (P15 or P30) [39] PLA + P A12.5 + P A25 + P (n = 115) (n = 111) (n = 113) prevented nor exacerbated this weight gain. All regimens were well tolerated; hypoglycemia was uncommon and generally mild-to-moderate in severity, although two severe cases were reported when alogliptin was added to pioglitazone and metformin [40] . Relative to pioglitazone m o n o t h e r a p y, a l o g l i p t i n -p i o g l i t a z o n e combination therapy was not associated with any meaningful differences in weight gain, incidence of hypoglycemia, AEs, serious AEs, or treatment discontinuations due to an AE.
DISCUSSION
The treatment of T2DM has long encompassed a stepwise approach beginning with diet and exercise and an oral antihyperglycemic agent,
followed by the addition of one or more agents as required in the event that glycemic control deteriorates. This approach is reactive rather than proactive as it is based around compensating for the progressive decline of betacell function that underlies the deterioration in glycemic control. It is now known that beta-cell failure occurs much earlier and is more severe than previously thought (>80% failure at the time of diagnosis) [22] , suggesting that a newer approach to T2DM treatment is warranted. In a Banting Lecture [23] , DeFronzo called for a paradigm shift in the management of T2DM based on the following principles.
1. Effective treatment of T2DM requires multiple drugs used in combination to correct multiple pathophysiological defects.
2. Treatment should be based on known pathogenic abnormalities and not simply on reduction of HbA 1c .
3. Therapy must be started early in the natural history of T2DM to prevent progressive beta-cell failure.
The combination of alogliptin and pioglitazone appears to address these more modern requirements for treatment of T2DM as these agents work by complementary mechanisms; alogliptin increases insulin secretion and decreases glucagon secretion after meals [11, 12] , whereas pioglitazone increases both peripheral and hepatic insulin sensitivity [13] . In an animal model of T2DM, the combination of alogliptin and pioglitazone administered at an early stage of diabetes was shown to improve beta-cell function and maintain islet structure to a greater extent than either component as monotherapy [34] .
Randomized controlled trials in which combination therapy with alogliptin and pioglitazone was investigated clinically in patients with T2DM provide strong and consistent clinical evidence for the efficacy of this particular combination. In these trials, alogliptin combined with pioglitazone was evaluated within the framework of several typical T2DM treatment backgrounds: alogliptin-pioglitazone as initial therapy in drug-naïve patients [37] ; alogliptin as add-on treatment to pioglitazone (± metformin or sulfonylurea) [38, 39] ; alogliptin as add-on treatment to pioglitazone + metformin [40] ; and alogliptin-pioglitazone as add-on treatment to metformin [41] . Hypoglycemia was uncommon and generally mild-to-moderate in severity, although two severe cases were reported when alogliptin was added to pioglitazone and metformin [40] .
Consistent with the known adverse effects of TZD, pioglitazone was associated with an increase in body weight [37, 38, 40] but alogliptin appeared to be weight-neutral as it neither prevented nor exacerbated weight gain.
It can be concluded from these results that the alogliptin-pioglitazone combination successfully meets the more modern requirements for treatment of T2DM as outlined above [23] been documented for other agents in this class, such as vildagliptin [42] , sitagliptin [43] [44] [45] , saxagliptin [46] , and linagliptin [47] .
The introduction of the fixed-dose combination alogliptin and pioglitazone in Japan 
